Ask about this productRelated genes to: ApoC2 protein
- Gene:
- APOC2 NIH gene
- Name:
- apolipoprotein C2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: ApoC2 protein
Related articles to: ApoC2 protein
- To investigate changes in serum lipid profile parameters combined with tumor markers in gastric cancer (GC) patients and their value in GC screening. - Source: PubMed
Lu JingboXu RunhaoLi TinghuaZheng BingLi Min - Finger citron (FC), a traditional plant with both pharmacological activity and food-grade safety, is considered to possess potential for the improvement of non-alcoholic fatty liver disease (NAFLD). However, the bioactive constituents responsible for this effect and their underlying mechanisms remain incompletely understood. In this study, an integrative approach combining network pharmacology, molecular docking, and in vitro validation was employed to elucidate the mechanisms by which FC exerts anti-NAFLD effects. Network pharmacology analysis identified 62 bioactive compounds targeting 306 liver injury-related genes, among these, 3,4,7-trimethoxycoumarin (TMC) was selected for further investigation. Gene Ontology (GO) enrichment revealed that FC-mediated effects were significantly associated with protein phosphorylation, inflammatory responses, and protein kinase activity, whereas Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment highlighted key involvement of the PI3K-Akt and MAPK signaling pathways. Molecular docking demonstrated high binding affinities between TMC and key target proteins including IL-6, TNF-α, albumin (ALB), AKT1, and STAT3. The successful synthesis of TMC was confirmed via H-NMR and MS analyses. In vitro studies revealed that TMC effectively reduced lipid accumulation and oxidative stress induced by free fatty acids in HepG2 cells. Furthermore, RT-qPCR analysis showed that TMC modulated the mRNA expression of key target genes and lipid metabolism-associated genes, including CPT2, and APOC2, thereby substantiating the mechanistic basis of its therapeutic action. Collectively, these findings highlight the therapeutic potential of FC against NAFLD and provide a scientific basis for its further development as a promising NAFLD intervention. - Source: PubMed
Publication date: 2026/04/03
Li QingpengSun HuilongChen XiaolingChen ChunyangChen YongshengHe HuiYang FanWang DanZhou Lin - Ultracentrifugation (UC) has long been considered the "gold standard" for extracellular vesicle (EV) isolation. However, due to its drawbacks such as high cost of an ultracentrifuge and rotors, time-consuming and labor-intensive protocol, low yield considering initial biofluid volume and low throughput, development of new EV isolation approaches is still ongoing. Here we compare three methods for isolating the most studied EV subtype, small extracellular vesicles (sEVs), from human plasma: ultracentrifugation (UC), express asymmetric depth filtration (ExADFi), and anti-CD9 immunoaffinity capture (AS-CD9) with focus on their Raman and proteomic profiles. For all three methods, purity and quality of the sEV isolation were assessed based on the level of contamination of the sEV fraction with major plasma proteins such as albumin and apolipoproteins (APOA1, APOH, APOA4, APOC2, APOC1, and APOC4). UC showed the highest ratio of protein to nanoparticle concentration. AS-CD9 and ExADFi provided comparable to UC purity and levels of non-vesicular contaminants with AS-CD9 requiring minimal time and labor. ExADFi showed characteristics including purity of the sEV samples, yield, and isolation time that is between the UC and AS-CD9 methods. Raman spectroscopy provided more details about characteristics of the isolated sEVs and confirmed differences observed in the proteomic profiles. The findings demonstrate that the AS-CD9 and ExADFi methods could be appropriate substitutes of the classical UC-based isolation method and be chosen depending on the final requirements and use of the purified sEVs such as further functional and biomarker studies. - Source: PubMed
Chernyshev Vasiliy SStarodubtseva Natalia LRimskaya Elena NBugrova Anna EKononikhin Alexey SSilachev Denis NTokareva Alisa OEvtushenko Ekaterina AYakovlev Alexander AYurin Alexander MKepsha Maria AMezhevitinova Elena ANikolaev Eugene NFrankevich Vladimir ENazarova Niso MPrilepskaya Vera NSukhikh Gennadiy T - This study established a hyperlipidemia model by feeding Sprague-Dawley rats a high-fat diet for 8 weeks. The rats were randomly assigned to the following groups: model group, atorvastatin calcium group(4.8 mg·kg~(-1)), low-, medium-, and high-dose Tanyu Tongzhi Optimization Decoction(TYTZD) groups(3.6, 7.2, and 14.4 g·kg~(-1)), and a normal diet control group. After 4 weeks of continuous administration, hematoxylin-eosin(HE) and oil red O staining were used to observe liver pathological changes and lipid infiltration. Automatic biochemical analyzer were performed to assess blood lipid profiles, coagulation function, and liver function. Transcriptomic and proteomic analyses were employed to identify differentially expressed genes(DEGs) and proteins(DEPs), followed by enrichment analysis. The MCODE algorithm was applied to classify DEGs and DEPs into modules, and network separation index(S_(AB)) was calculated to assess module separation, enabling construction of a gene-protein co-expression network for core target screening. The diagnostic accuracy of core targets was evaluated by area under the receiver operating characteristic(ROC) curve(AUC), and ELISA was used to measure core target expression. Western blot detected the expression of core pathway-related proteins in liver tissue. RESULTS:: demonstrated that TYTZD significantly improved dyslipidemia, coagulation dysfunction, liver injury, hepatic pathology, and lipid infiltration in hyperlipidemic rats. Transcriptomic analysis identified 571 DEGs significantly reversed by TYTZD, mainly enriched in inflammatory signaling pathways such as Toll-like receptor 4(TLR4)/nuclear factor-κB(NF-κB). Proteomic analysis identified 102 reversed DEPs, mainly involved in cholesterol metabolism pathways. Integrated analysis identified core targets including TLR4, tumor necrosis factor-α(TNF-α), integrin subunit alpha M(ITGAM), Toll-like receptor 2(TLR2), matrix metalloproteinase 9(MMP9), interleukin-1β(IL-1β), apolipoprotein E(APOE), and apolipoprotein C2(APOC2), all with AUC values greater than 0.70. ELISA showed that TYTZD intervention significantly downregulated MMP9, TNF-α, IL-1β, TLR2, ITGAM, and TLR4, and upregulated APOC2 and APOE. Western blot indicated that TYTZD reduced TLR4, p-NF-κB, and IL-1β protein expression in liver tissue. In conclusion, TYTZD may exert anti-hyperlipidemic effects through regulation of core targets such as ITGAM, TLR4, and APOC2, and by modulating the TLR4/NF-κB signaling pathway to intervene in inflammatory responses and cholesterol metabolism, thereby achieving multi-target, multi-pathway therapeutic effects against hyperlipidemia. - Source: PubMed
Yang YingLi XiangTang Dan-LiLi BingWu Si-JiaZong Wen-JingZhang Hua-Min - Apolipoproteins (APOs) are essentially structural and functional components of lipoproteins, which are composed of 22 members and their effects on certain types of cancer have been studied. However, their roles in endometrial cancer (EC), which is one of the most common malignant tumors in gynecology were unclear and rarely investigated. - Source: PubMed
Publication date: 2026/02/16
Zhou LinaWang RenchengDu GuiqiangWu YupengLi HuiHe YinyanYe ZhikangXiang Jiangdong